What is dMed Biopharmaceutical?
dMed Biopharmaceutical operates within the dynamic biopharmaceutical industry, focusing on advancing clinical research and development. The company leverages its expertise to partner with innovation-driven biopharmaceutical firms, offering professional clinical trial execution and agile capabilities for complex studies. With a foundation built on over two decades of experience, dMed Biopharmaceutical provides patient-centered clinical trial solutions designed to deliver high-quality data and mitigate risks. Their global footprint, spanning more than 40 countries, enables them to access diverse patient populations, thereby supporting groundbreaking advancements and clinical achievements. The company's strategic approach is centered on aligning with client objectives to generate valuable insights for future progress in clinical research.
How much funding has dMed Biopharmaceutical raised?
dMed Biopharmaceutical has raised a total of $158M across 3 funding rounds:
Series A
$8M
Series B
$50M
Series C
$100M
Series A (2016): $8M with participation from Tairui Investment, Qiming Venture Capital, and Zai Lab
Series B (2019): $50M led by Vivo Capital, Legend Capital, Qiming Venture Partners, and Lilly Asia Ventures
Series C (2020): $100M supported by Kaiser Foundation Hospital, Fidelity Management Services Inc, Sequoia Capital Operations LLC, and E Fund Management Co. Ltd
Key Investors in dMed Biopharmaceutical
Sequoia Capital Operations LLC
Sequoia Capital Operations LLC is a venture capital firm known for its long-term investment approach and active partnership with entrepreneurs. They invest across venture, growth, and late-stage opportunities, with a global track record of backing market leaders.
Qiming Venture Capital
Qiming Venture Capital is a prominent venture capital firm that focuses on investing in innovative companies across technology, healthcare, and artificial intelligence, providing industry resources and strategic guidance to support startup growth.
Vivo Capital
Vivo Capital is a global healthcare investment firm founded in 1996, focusing on private and public equity as well as venture capital investments within the healthcare sector.
What's next for dMed Biopharmaceutical?
The recent major enterprise-level funding and strategic investment signal a new phase of expansion and development for dMed Biopharmaceutical. This capital infusion is expected to fuel further research initiatives, enhance operational capabilities, and potentially broaden their global reach. The company is well-positioned to capitalize on emerging opportunities in the biopharmaceutical landscape, likely focusing on scaling its services, forging new strategic partnerships, and accelerating the delivery of innovative clinical trial solutions. This significant backing suggests a strong investor confidence in dMed Biopharmaceutical's business model and its potential to drive substantial impact in the healthcare sector.
See full dMed Biopharmaceutical company page
